RCM
KERX

Rotella Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Rotella Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-21,000
Closed -$74K – 643
2015
Q3 		$74K Buy
+21,000
New +$141K 0.02% 457

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Rotella Capital Management's KERX Position: Q4 2015 in Review

Rotella Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2015, closing a stake of 21,000 shares — an estimated $74K sold.

Rotella Capital Management first reported a position in KERX in Q3 2015 and held it in 1 quarter. The position peaked at $74K in Q3 2015. 128 funds tracked by Wall St. Rank hold KERX as of Q4 2015.

  • Rotella Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • Rotella Capital Management sold 21,000 Keryx Biopharmaceuticals Inc shares in Q4 2015, an estimated $74K.
  • Rotella Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q3 2015 and held it in 1 quarter.
  • Rotella Capital Management's Keryx Biopharmaceuticals Inc position peaked at $74K in Q3 2015.
  • 128 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2015.

Based on Rotella Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.